Holen Sie sich die Stockscreener-App
1.85
1.09%
0.02
Handel nachbörslich:
1.85
Schlusskurs vom Vortag:
$1.83
Offen:
$1.83
24-Stunden-Volumen:
155.52K
Relative Volume:
0.27
Marktkapitalisierung:
$96.78M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-1.0335
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
+4.52%
1M Leistung:
+28.47%
6M Leistung:
-26.59%
1J Leistung:
-73.15%
1-Tages-Spanne:
$1.78
$1.87
1-Wochen-Bereich:
$1.75
$1.9399
52-Wochen-Spanne:
$1.02
$7.44
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.85 | 100.17M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan Therapeutics Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
What analysts say about TScan Therapeutics Inc. stockBreakthrough stock performance - jammulinksnews.com
What drives TScan Therapeutics Inc. stock priceTremendous return rates - jammulinksnews.com
Is TScan Therapeutics Inc. a good long term investmentOutstanding investment returns - Autocar Professional
One TScan Therapeutics Insider Raised Stake By 18% In Previous Year - Yahoo.co
Why TScan Therapeutics Inc. stock attracts strong analyst attentionStrategic High Profit Opportunities - Newser
How TScan Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
What makes TScan Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - Newser
TScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street Zen - Defense World
Great week for TScan Therapeutics, Inc. (NASDAQ:TCRX) institutional investors after losing 73% over the previous year - simplywall.st
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 4% – Time to Sell? - Defense World
TScan Therapeutics Elects New Directors at Annual Meeting - TipRanks
TScan Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from Russell Microcap Growth Index - MarketScreener
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80 - Defense World
Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell - Defense World
Bank of America Corp DE Has $456,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Wellington Management Group LLP Boosts Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
ProShare Advisors LLC Makes New $40,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BNP Paribas Financial Markets Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - Barchart.com
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Stifel Financial Corp Acquires 10,567 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):